Immunomodulator Market Report 2026

The immunomodulator market size has grown strongly in recent years. It will grow from $237.02 billion in 2025 to $255.25 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to rising prevalence of autoimmune disorders, expansion of oncology and transplant procedures, increased use of corticosteroids and traditional immunosuppressants, growing hospital-based immunotherapy adoption, improved clinical understanding of immune pathways.

The immunomodulator market size is expected to see strong growth in the next few years. It will grow to $327.94 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of novel biologics and small molecule agents, rising demand for immuno-oncology therapies, increasing focus on targeted and safer immunomodulators, growth of home-based and outpatient treatments, expanding applications in emerging infectious and inflammatory diseases. Major trends in the forecast period include increasing adoption of biologic and targeted immunotherapies, growing use of combination immunomodulatory treatments, rising focus on personalized and precision immunotherapy, expansion of immunomodulators in chronic and autoimmune diseases, increasing shift toward outpatient and long-term immune management.

The rise in chronic diseases is expected to drive the growth of the immunomodulator market. Chronic diseases are long-term medical conditions that generally develop gradually and persist for years or even a lifetime. Their increasing prevalence is influenced by factors such as aging populations, lifestyle choices, genetic predispositions, and the availability of healthcare infrastructure. Immunomodulators offer valuable therapeutic options for managing chronic conditions by modulating immune responses, reducing inflammation, preventing organ rejection, enhancing immune surveillance, and improving symptom management. For instance, in September 2023, according to the World Health Organization, 41 million deaths occurred globally due to non-communicable or chronic diseases, accounting for 74% of total deaths. These included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Therefore, the rise in chronic diseases is propelling the immunomodulator market.

Major companies in the immunomodulator market are focusing on developing non-immunosuppressive products to meet the growing demand for therapies that modulate the immune system without compromising overall immune function. Non-immunosuppressive therapies are designed to target specific immune pathways while preserving the body’s general immunity. For example, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, initiated early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is designed for patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA granted fast-track designation for NVG-2089 in bullous pemphigoid. This recombinant, non-immunosuppressive immunomodulator targets type II Fc receptors to activate an endogenous regulatory mechanism that reduces autoimmune dysregulation. The trial aims primarily to assess safety and tolerability, with secondary objectives evaluating pharmacokinetics and pharmacodynamics.

In May 2024, Biogen Inc., a US-based biotechnology company specializing in therapies for neurological and rare diseases, acquired Human Immunology Biosciences (HI Bio) for $1.15 billion upfront, with up to $650 million in milestone payments. This acquisition provides Biogen access to HI Bio’s late- and early-stage immunology pipeline, including the monoclonal antibody felzartamab and an anti-C5aR1 program. This expands Biogen’s capabilities in immune-mediated diseases, enhances its pipeline depth, diversifies therapeutic offerings, and strengthens long-term growth potential. HI Bio is a US-based clinical-stage biotechnology company known for precision therapies targeting severe immune-mediated diseases, with expertise in immunomodulatory antibody programs.

Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Kyowa Kirin Co. Ltd.

North America was the largest region in the immunomodulator market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunomodulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the immunomodulator market by increasing costs of imported biologics, active pharmaceutical ingredients, and advanced manufacturing inputs, impacting drug pricing and availability. These effects are most pronounced in regions dependent on imported specialty drugs, including asia-pacific and latin america. However, tariffs are also encouraging local production of biologics and small molecule immunomodulators, strengthening domestic supply chains and supporting long-term market resilience.

The immunomodulator market research report is one of a series of new reports that provides immunomodulator market statistics, including immunomodulator industry global market size, regional shares, competitors with a immunomodulator market share, detailed immunomodulator market segments, market trends and opportunities, and any further data you may need to thrive in the immunomodulator industry. This immunomodulator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An immunomodulator is a substance or medication that regulates or alters the activity of the immune system. It is used to treat a variety of medical conditions by modulating immune responses according to the underlying disease and the intended effect on immunity.

The main product types in the immunomodulator market include immunosuppressants, immunostimulants, and other related products. These medications either suppress or stimulate the immune system, depending on therapeutic requirements. Key distribution channels comprise hospital pharmacies, online pharmacies, retail pharmacies, and other platforms. Immunomodulators are applied across various therapeutic areas such as oncology, respiratory diseases, human immunodeficiency virus (HIV), and other indications, and are utilized by end users including hospitals, clinics, and other healthcare facilities.

The immunomodulator market consists of sales of herbal immunomodulators, vaccines, immunomodulatory drugs, monoclonal antibodies, and interferons. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.